DENVER, Colo. (247marketnews.com) – The market is once again rewarding investors willing to look beyond the headline indexes; NeOnc Technologies Holdings (NASDAQ:NTHI), Armata Pharmaceuticals (NYSEAMERICAN:ARMP), Definium Therapeutics (NASDAQ:DFTX), Basel Medical Group (NASDAQ:BMGL), Blue Moon Metals (NASDAQ:BMM) and The Elmet Group (NASDAQ:ELMT).
NeOnc Technologies Holdings: The Insider-Buying Story Gets More Interesting
There is insider buying, and then there is insider buying that arrives while the underlying clinical story is moving toward a potentially important regulatory decision. NeOnc (NASDAQ:NTHI) has now put together a sequence of events that small-cap biotech traders are likely to follow closely: positive Phase 2a NEO100 data, an anticipated FDA discussion about a registrational pathway, a new institutional financing and continued open-market purchases by management. NeOnc announced a $15 million registered direct offering priced at $4.20 per share plus accompanying warrants, with gross proceeds expected to be approximately $15 million.
The clinical catalyst is the bigger story. NeOnc reported that its Phase 2a NEO100 study in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma produced a six-month progression-free survival rate of 48.9%, versus the study’s prespecified 20% benchmark, with a reported median overall survival of 26.09 months. The company said five of 24 patients remained on treatment and that it planned to request a Type B meeting with the FDA to discuss a potential registrational development path. NeOnc CEO Amir F. Heshmatpour described the next step directly: “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study.”
That makes the reported insider activity particularly attention-grabbing. Heshmatpour’s additional purchase of 37,000 shares at a reported weighted-average price of $3.6654 would represent roughly $135,620 of stock bought below the $4.20 financing price. The significance is less about the dollar amount than the pattern: management buying while the company is simultaneously advancing toward an FDA discussion and has just secured institutional capital.
Armata Pharmaceuticals: FDA Breakthrough Therapy Designation Changes the Game
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) has just delivered the kind of regulatory headline capable of instantly changing the conversation around a small-cap biotech. The FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia, including infections caused by both methicillin-sensitive and methicillin-resistant strains. The designation is particularly significant because Breakthrough Therapy status is intended for serious or life-threatening diseases where preliminary clinical evidence suggests the potential for substantial improvement over available therapies.
The designation builds on Armata’s earlier clinical work rather than appearing out of nowhere. The company’s Phase 1b/2a diSArm study evaluated intravenous AP-SA02 alongside best available antibiotic therapy. Armata has reported that AP-SA02 produced higher and earlier clinical cure rates than placebo plus standard therapy and that no patients receiving AP-SA02 demonstrated non-response or relapse at the end-of-study assessment in the company’s reported analysis. Its SEC filing also describes the candidate as having shown earlier cure and no evidence of relapse four weeks after therapy in the Phase 2a dataset.
The regulatory stack is now becoming unusually compelling for a company of Armata’s size. AP-SA02 already has Fast Track and Qualified Infectious Disease Product designations, and Breakthrough Therapy designation adds another layer of FDA engagement. Armata has also been preparing for a Phase 3 superiority study, with the company previously reporting that it had submitted the Phase 3 protocol and responses to FDA feedback and completed four engineering manufacturing runs. The company has said the Phase 3 study is anticipated to begin in the second half of 2026.
Definium Therapeutics: The Psychedelic Biotech Story Is Moving Toward the Finish Line
Definium Therapeutics (NASDAQ:DFTX) is building a much larger clinical narrative around DT120 ODT, its proprietary orally disintegrating formulation of lysergide. The latest development is another positive Phase 3 result in generalized anxiety disorder. Panorama reportedly met its primary and key secondary endpoints, with the 100-microgram dose producing a placebo-adjusted 5.1-point improvement in HAM-A at Week 12 and a Cohen’s d of 0.64. The company also reported that the treatment effect emerged rapidly, with differences visible as early as Day 2.
The significance goes beyond a single trial. Panorama is the company’s second positive Phase 3 study in GAD and follows the positive Emerge Phase 3 study in major depressive disorder and the earlier Voyage GAD study. Emerge previously produced an 8.1-point placebo-adjusted improvement in MADRS at Week 6 and a 7.3-point difference at Week 12.
Definium entered the Panorama readout with approximately $1.1 billion in cash, cash equivalents and investments as of June 30, 2026, which provides a considerably different financial backdrop from many small-cap biotechnology companies.
The commercial story is therefore becoming more interesting. Definium says it expects a pre-NDA meeting with the FDA in the fourth quarter of 2026 and anticipates an NDA filing in the first half of 2027. At the same time, the company is developing DT120 across GAD, MDD and PTSD. The key question for investors is no longer simply whether the drug can produce a measurable clinical effect; it is whether the growing collection of Phase 3 data can translate into an approvable, commercially viable treatment paradigm.
Basel Medical Group: No Headline, Low Float, and Stock Traders Are Watching
Basel Medical (NASDAQ:BMGL) is a completely different type of setup. Unlike the biotech names above, the company has not announced a comparable new clinical or regulatory catalyst. Instead, the attraction is centered on trading dynamics surrounding a very small-cap Singapore-based healthcare operator. Basel Medical provides orthopedic and trauma care, sports medicine, surgery, neurosurgical treatment, rehabilitation, occupational medicine and other healthcare services in Singapore.
That distinction matters because a stock can move dramatically without a corresponding fundamental announcement, particularly when liquidity is thin. Historical trading data show BMGL regularly changing hands in relatively small volumes, while the stock experienced several sharp percentage moves during August.
There is also important corporate-action history behind the ticker. Basel Medical completed a one-for-twelve reverse stock split effective June 22, 2026, reducing the number of ordinary shares outstanding from approximately 18.8 million to about 1.57 million, subject to rounding. Nasdaq subsequently reported that the company regained compliance with the exchange’s $1 minimum-bid requirement in July.
Blue Moon Metals and The Elmet Group: Tungsten Suddenly Has Very Big U.S. Story and the $450M Headline Could Be Just the Beginning
Blue Moon Metals (NASDAQ:BMM) just moved its Springer tungsten project into a dramatically more consequential strategic framework. Blue Moon, The Elmet Group and EQ Resources announced a binding letter agreement covering a proposed series of transactions involving the Springer Tungsten Complex in Nevada, including a joint venture for the site’s ammonium paratungstate, or APT, plant. The contemplated project investment is approximately $150 million, with an additional $25 million reserved for standby requirements.
The structure is notable because it goes well beyond a conventional mining financing. The proposed transaction includes a $50 million tungsten prepayment facility for Blue Moon, a $25 million equity subscription by The Elmet Group (NASDAQ:ELMT), and a $75 million capital contribution to the APT plant joint venture. The proposed ownership of the APT JV is 70% for The Elmet Group, 20% for Blue Moon and 10% for EQ Resources. Blue Moon would retain ownership and operation of the mine and mill. Blue Moon’s own project materials describe Springer as a multi-phase tungsten development in Nevada intended to leverage existing infrastructure and a broader hub-and-spoke critical-metals strategy.
The potential timeline is what makes the story especially interesting. Blue Moon has previously targeted a return of the Springer mine and mill to production in the fourth quarter of 2027, while the APT plant is targeted for restart in the second half of 2028. If achieved, the project could become a meaningful North American source of tungsten concentrate and APT. The project also sits within a broader push to build Western critical-mineral supply chains, a theme that has increasingly become a major source of capital for companies operating in strategically important commodities.
The Elmet Group also announced a $450 million committed investment from the U.S. Department of War intended to expand tungsten manufacturing, secure raw-material access and strengthen mining and processing capacity. The company also announced plans for a new Elmet Refining & Trading division designed to coordinate sourcing, processing and material delivery across its expanding supply network.
The more eye-catching number may be the separate Defense Logistics Agency agreement. Elmet Technologies, an ELMT subsidiary, has received an indefinite-delivery/indefinite-quantity contract with a ceiling value of up to $2 billion to support rebuilding the U.S. National Defense Stockpile, including a guaranteed funded commitment of $150 million. Reuters reported on September 14 that the agreement is intended to strengthen the U.S. tungsten supply chain and rebuild the National Defense Stockpile.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.